DrugBaron

JULY 19, 2022

Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.

Small Molecule 100

Small Molecule Drugs DNA Pharma Companies 100

Drug Target Review

JUNE 6, 2025

With an extensive background in small molecule chemistry, bioconjugation and protein science, these expert teams are leading efforts to place payload development at the centre of ADC innovation. The ADC itself is not necessarily a large molecule – it’s a small molecule with aspects of a large molecule, and vice versa.

Small Molecule 52

Small Molecule Pharmacokinetics Packaging Drugs 52

Covalent Modifiers

JUNE 24, 2024

Rullo, Molecular Therapy: Oncology , 2024 , 200842, [link] Proximity-induction of cell-cell interactions via small molecules represents an emerging field in basic and translational sciences. Lake, Galina Denisova, Joanne A. Hammill, Jonathan L. Bramson, Anthony F.

Small Molecule 130

Small Molecule Engineering Science Therapies 130

Alta Sciences

JULY 3, 2025

Because this transformation can significantly improve the stability, solubility, and overall performance of pharmaceutical compounds, especially when it comes to small molecules. Beyond the science, what’s exciting is how this technology opens doors. The response? The response? Ready to advance your next project?

Small Molecule 52

Small Molecule Drug Development Pharmaceuticals Science 52

Drug Target Review

JULY 10, 2025

Before a compound can become a viable therapy, it must pass a series of tests – not just for potency, but for how it behaves in the body. Absorption, distribution, metabolism, excretion and toxicity – collectively known as ADMET – are among the most critical and challenging hurdles in small molecule drug discovery.

Metabolic Stability 73

Metabolic Stability Drugs Drug Development Small Molecule 73

Drug Target Review

APRIL 7, 2025

As our understanding of the underlying biology of disease grows more sophisticated, emerging therapies operate on increasingly complex biopathological systems and mechanisms. Safety biomarkers account for adverse effects of a therapy under study. There are several types of biomarkers to consider.

Clinical Development 69

Clinical Development Clinical Trials Clinical Pharmacology Trials 69

The Pharma Data

NOVEMBER 17, 2020

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. . This includes therapies against the nuclear receptor ROR?t,

Small Molecule 52

Small Molecule Disease Immune Response Licensing 52

Drug Target Review

JUNE 2, 2025

Bioconjugates are rapidly emerging as a key frontier in targeted therapies, particularly through Antibody-Drug Conjugates (ADCs) , which combine antibodies with cytotoxic drugs to deliver more precise and effective treatments. Very often, you have a payload that is extremely toxic, and then you require specially trained people to handle it.

Small Molecule 52

Small Molecule Engineering Therapies Drugs 52

The Pharma Data

JUNE 25, 2025

Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc. , a biotechnology firm known for its expertise in microRNA-targeting therapies.

RNA 52

RNA Clinical Trials Disease Small Molecule 52

Drug Target Review

JULY 3, 2025

New approach methodologies data In April, the US Food and Drug Administration (FDA) announced a plan to replace animal testing in the development of monoclonal antibodies and other therapies with validated “human-relevant” methods, including AI-based computational models evaluating toxicity, cellular lines and organoid toxicity.

Drug Development 64

Drug Development Drugs Animal Testing Engineering 64

Broad Institute

OCTOBER 4, 2023

By Allessandra DiCorato October 4, 2023 Credit: AbbVie The new small molecule inhibitor (green) sits inside the PTPN2 protein, where acidic sites are marked in red and basic sites are marked in blue. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy.

Small Molecule 128

Small Molecule Clinical Trials Trials Engineering 128

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

JUNE 15, 2023

In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop small molecule therapeutics to target RNA processing. It is somewhat like how PROTACs have changed the perspective on what is a tractable therapeutic target.

RNA 96

RNA Small Molecule Disease Assay Development 96

DrugBank

OCTOBER 17, 2024

Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drug development lifecycle. These complex molecules require precise engineering to ensure optimal efficacy and safety.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

LifeSciVC

APRIL 2, 2024

The quality of science – and the ability to distinguish it from other approaches – was the entry ticket to serious engagement. The science presents an opportunity and a challenge for us at Sionna. The science presents an opportunity and a challenge for us at Sionna. That science resonates with investors.

Science 83

Science Small Molecule International Clinical Development 83

Drug Target Review

JUNE 11, 2025

Drug development faces significant challenges: long timelines, high costs , complex processes and low probabilities of success (PoS), exacerbated by the shift towards more complex molecules, biologics and cell and gene therapies, hindering patient access to vital treatments.

Drugs 64

Drugs Clinical Trials Drug Development Pharmaceuticals 64

Drug Target Review

JULY 23, 2024

I studied Natural Sciences at the University of Cambridge, where I was exposed to a range of disciplines from chemistry to physiology, specialising in my last year in biochemistry. Pushing the boundaries of science always opens the door to new, impactful developments, although there are always challenges along the way.

Small Molecule 116

Small Molecule Targeted Protein Degradation Science Disease 116

Drug Target Review

SEPTEMBER 25, 2024

Most targeted cancer therapies used today operate by inhibiting targets along well-known oncogenic signalling cascades. The reactivation of oncogenic signalling upstream or downstream of the driving oncogene is a well-studied source of resistance to targeted cancer therapies.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

DrugBank

MAY 15, 2024

This method was more about serendipity than science. Today, we're able to identify and target specific molecules involved in disease processes—a method that's much more like using a sniper rifle than throwing darts blindfolded. One approach is to look beyond the traditional drug molecule.

Small Molecule 98

Small Molecule Molecular Biology Drugs Disease 98

Drug Target Review

NOVEMBER 6, 2023

2 It is this complexity that necessitates powerful, targeted combination therapies. 4, 5 More recently, new combination regimens have emerged that incorporate targeted therapies to treat a variety of blood cancers, including multiple myeloma (MM), chronic lymphocytic leukaemia (CLL) and acute myelogenous leukaemia (AML).

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. Small molecule GLP1s?

Small Molecule 143

Small Molecule Trials Therapies Disease 143

The Pharma Data

JUNE 24, 2025

As part of the extended agreement, Bayer will continue to provide funding, technical support, and strategic guidance for joint projects, while also offering resources and recognition to Tsinghua’s scientists who are driving forward life sciences innovation.

Pharma R&D 40

Pharma R&D Pharmaceutical Companies Pharmaceuticals Science 40

The Pharma Data

NOVEMBER 15, 2020

In a deal set to be finalized early in 2021, Urovant Sciences has agreed to be fully acquired by largest investor and close partner, Sumitovant Biopharma. The company hopes to follow vibegron to the market with URO-902, a novel gene therapy for patients whose OAB has eluded oral pharmacologic therapy.

Science 52

Science Small Molecule FDA Approval Therapies 52

Drug Target Review

MAY 6, 2024

Luckily, my love for science remained. The clinical efficacy of BRAF inhibitors, like most other targeted cancer therapies, is inevitably limited by resistance development. We found that, indeed, cancer’s earliest defence mechanisms are triggered almost immediately after exposure to a targeted cancer therapy.

Therapies 105

Therapies Science Small Molecule Clinical Trials 105

The Pharma Data

JUNE 9, 2025

The acceptance, which follows the CDE’s grant of Priority Review status in May, represents an accelerated regulatory pathway for what may become the first approved systemic therapy for TGCT in China. Pimicotinib: A Promising CSF-1R Inhibitor Pimicotinib is an investigational small molecule developed by Abbisko Therapeutics Co.,

Treatment 40

Treatment Therapies Small Molecule Marketing 40

DrugBank

JANUARY 9, 2025

Targeted Therapies vs. Traditional Treatments Traditional cancer treatments, such as chemotherapy and radiotherapy, are inherently cytotoxic, targeting both cancerous and healthy cells. The development of imatinib to treat chronic myeloid leukemia (CML) serves as a hallmark for targeted therapies.

Therapies 52

Therapies Disease Treatment Small Molecule 52

KIF1A

JANUARY 27, 2024

Rare Roundup KRIBB develops new gene therapy candidate for hereditary spastic paraplegia This week we’re flipping the format and starting with our Rare Roundup, after families contacted us with this article about a gene therapy candidate for hereditary spastic paraplegia.

Therapies 111

Therapies Small Molecule DNA Treatment 111

Drug Target Review

JUNE 16, 2025

Targeted drug delivery and therapeutic development MSI offers significant advantages for those developing small molecule therapeutics. 7 In immune therapies, MSI helps monitor immune-cell distribution and off-target effects, optimising therapeutic strategies and improving patient outcomes. For instance, Cheng et al.

Drugs 52

Drugs Organic Chemistry Laboratories Pharmaceuticals 52

Drug Target Review

SEPTEMBER 11, 2024

How does morADC technology combine the properties of small molecules and monoclonal antibodies to enhance anti-aggregation effects for CNS applications? The morADC are able to cross the blood-brain barrier more efficiently and offer higher potency than individual parent molecules.

Small Molecule 52

Small Molecule Disease Therapies Drugs 52

The Pharma Data

JUNE 22, 2023

Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan SANTA MONICA, Calif.–(BUSINESS to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc. .–(BUSINESS to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc.

Therapies 40

Therapies Marketing Small Molecule Science 40

LifeSciVC

JULY 8, 2025

Over the past two decades, life sciences venture capital has developed a substantial body of data, pattern recognition, and tacit knowledge around what works in early-stage biotech. The structures that support them, how we align, coordinate, and decide, may need to evolve as much as the science they advance.

Hospitals 57

Hospitals Small Molecule Science Nurses 57

The Pharma Data

MARCH 30, 2021

(NASDAQ:AMGN) and Rodeo Therapeutics Corporation (Rodeo) today announced an agreement under which Amgen will acquire Rodeo, a privately held biopharmaceutical company based in Seattle that develops small-molecule therapies designed to promote regeneration and repair of multiple tissues. About Rodeo Therapeutics.

Small Molecule 52

Small Molecule Therapies Disease Science 52

The Pharma Data

JUNE 28, 2021

Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

NIH Director's Blog: Drug Development

OCTOBER 11, 2022

That’s quite a testament to the world-leading science that NIH pursues and its continued impact on improving human health and well-being. Barry Sharpless, Scripps Research, La Jolla, CA, October 5, 2022 marked the second time that he’s received an early-morning congratulatory call from The Royal Swedish Academy of Sciences.

Research 52

Research Small Molecule Science Clinical Research 52

Precision for Medicine

JUNE 26, 2023

Baseline Control’s expertise will become part of Project Farma, Precision for Medicine’s existing biomanufacturing strategy and execution group, expanding the scope of its manufacturing solutions for life science companies and driving greater speed and efficiency in bringing new drugs to market. For more information, visit projectfarma.com.

Science 40

Science Small Molecule Clinical Research Engineering 40

The Pharma Data

JULY 15, 2021

This extension will further help connect life-science innovators in Victoria to accelerate their healthcare solutions across the globe,” said Stacy Feld, Regional Head, Johnson & Johnson Innovation LLC, West North America, Australia & New Zealand.

Government 52

Government Science Pharmaceuticals Pharmaceutical Companies 52

Dark Matter Blog

JULY 19, 2021

Or should I say back to retirement, as he was comfortably relaxing at home back in 2016 when Jen Petter lured him back into the fray with the siren call of developing a new class of RNA-targeted small-molecule medicines here at Arrakis. I won’t dwell on Jim’s many accomplishments here. Don’t be a stranger!

Small Molecule 52

Small Molecule RNA Science Therapies 52